Acute Megakaryoblastic Leukemia

(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol, (S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethylamino-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile, 1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine, 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea, 1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, 1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3- tert-butyl-urea, 2-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)acetamide, tetrahydrochloride, 2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate, 2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}- 1H-pyrazol-3-yl)amino]- quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate, 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one, 225Ac-lintuzumab, 26 base single stranded phosphodiester DNA oligonucleotide, 5'-O-(trans-9"-octadecenoyl)-1-ß-D-arabinofuranosyl cytosine, 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate, Allogeneic T cells encoding an exogenous TK gene, Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2, Allogeneic ex vivo expanded umbilical cord blood cells, Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells, Allogeneic human dendritic cells derived from a CD34+ progenitor cell line, Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2, Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells / allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells, Alvocidib, Amonafide L-malate, Antisense oligonucleotide 5'-d[P-Thio} (CCCTG CTCCC CCCTG GCTCC)-3', Arsenic trioxide ( Arsenic Trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac, TRISENOX ), Azacitidine ( AZACITIDINE ACCORD, AZACITIDINE BETAPHARM, AZACITIDINE CELGENE, AZACITIDINE MYLAN, VIDAZA ), Bisantrene hydrochloride, Clofarabine ( CLOLAR, EVOLTRA, IVOZALL ), Combretastatin A1 diphosphate-, Crenolanib besylate, Daunorubicin (liposomal), Decitabine ( DACOGEN ), Devimistat, Donor lymphocyte preparation depleted of functional alloreactive T-cells, Enasidenib ( IDHIFA ), Entospletinib, Eryaspase ( GRASPA ), Fully human IgG1 antibody specific for CD33, Gemtuzumab Ozogamicin ( MYLOTARG ), Gilteritinib ( XOSPATA ), Glasdegib ( DAURISMO ), Guadecitabine, Histamine dihydrochloride ( CEPLENE ), Homoharringtonine ( CEFLATONIN ), Human monoclonal antibody against inhibitory killer cell lg-like receptors (1-7 F9), Idasanutlin, Inecalcitol, Isocitrate dehydrogenase 2-mutant inhibitor, Ivosidenib ( TIBSOVO ), L-Asparaginase ( KIDROLASE, SPECTRILA ), Laromustine ( CLORETATZNE ), Lestaurtinib, Lintuzumab, Liposomal combination of cytarabine and daunorubicin ( VYXEOS ), Liposomal daunorubicin, Midostaurin ( RYDAPT ), Mitoxantrone ( NOVANTRONE ), N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide, N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1- b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt, N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride, NEDD8-activating enzyme (NAE) inhibitor, Onvansertib, P-ethoxy growth factor receptor-bound protein 2 (Grb2) antisense oligonucleotide, Plerixafor ( MOZOBIL ), Pracinostat, Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3, Recombinant human interleukin-3 truncated diphtheria toxin fusion protein ( ELZONRIS ), Ribonucleotide reductase R2 specific phosphorothioate oligonucleotide, Sapacitabine, Selinexor ( XPOVIO ), Tamibarotene, Tipifarnib ( ZARNESTRA ), Tosedostat, Troxacitabine, Ulocuplumab, Vadastuximab talirine, Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3), Venetoclax ( VENCLEXTA, VENCLYXTO ), Volasertib, Vosaroxin, Wilms' tumour 1 (WT1) vaccine, Zosuquidar trihydrochloride, cenisertib, cusatuzumab, haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate, humanised monoclonal antibody of the IgG4 kappa isotype targeting CD47, lysine-specific histone demethylase (LSD1, also known as KDM1A) inhibitor